Novo Nordisk's CagriSema Falls Short in Head to Head Trial vs Zepbound Bryce Platt, PharmD posted on the topic LinkedIn Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Retatrutide, Retatrutide vs. Tirzepatide, Retatrutide vs. Semaglutide, Retatrutide vs. Cagrilintide CagriSema vs Tirzepatide: Weight Loss Results in REDEFINE 4 Trial Paramesh Shamanna posted on the topic LinkedIn